Raw Materials & Excipients Management – Page 10

Unjustified in-house specification during submission support – preventing repeat observations

Identifying the symptoms related to unjustified in-house specifications is the first step towards a thorough investigation. Common signals may include:Click to read the full article.

Pharmacopoeial change not implemented during routine testing – CAPA for compendial failures

Identifying symptoms or signals in the manufacturing or quality control environments is crucial for early detection of issues stemming from unimplemented pharmacopoeial changes. Here are the typical signs that may…

Specification not harmonized during supplier qualification – regulatory enforcement risk

A lack of specification harmonization typically manifests through various symptoms on the manufacturing floor and in the laboratory. Key indicators include:Click to read the full article.

Specification not harmonized during supplier qualification – inspection-ready justification strategy

Detecting non-harmonized specifications typically begins with visible symptoms that manifest during routine quality control checks or throughout the manufacturing process. Key signals indicating specification discrepancies include:Click to read the full…

Pharmacopoeial change not implemented during inspection – regulatory enforcement risk

Identifying the early symptoms or signals related to pharmacopoeial changes not implemented can significantly mitigate risks. Common indicators include:Click to read the full article.

Impurity profile drift detected during deviation investigation – CAPA aligned to GMP expectations

The initial detection of impurity profile drift can manifest as various signals within the manufacturing environment or laboratory analyses. Common symptoms include:Click to read the full article.

Polymorphic form inconsistency during supplier change – regulatory impact assessment

Detecting polymorphic form inconsistency can manifest itself through multiple channels that may include:Click to read the full article.

Moisture sensitivity overlooked during stability assessment – risk assessment for excipient choice

The first step in addressing moisture sensitivity concerns is recognizing the symptoms or signals that indicate a problem may exist. Common signals might include:Click to read the full article.

Unjustified excipient choice during scale-up – risk assessment for excipient choice

Detecting the symptoms of unjustified excipient choices is paramount for early intervention. Common signals may include:Click to read the full article.

Excipient incompatibility with API during scale-up – risk assessment for excipient choice

Identifying the symptoms of excipient incompatibility at an early stage can significantly reduce product risk and ensure compliance with quality standards. Common signals include:Click to read the full article.

Variability in excipient grade during formulation development – CAPA for formulation failures

Identifying the symptoms of excipient variability is critical for prompt investigation and resolution. Practitioners should be vigilant for specific indicators that point towards formulation failures linked to excipients. Common symptoms…

Excipient incompatibility with API during formulation development – risk assessment for excipient choice

Recognizing the symptoms of excipient incompatibility is crucial for timely intervention. These signs can manifest during various stages of formulation development, production, and stability testing. Some key symptoms include:Click to…